|
1
|
Orecchia R, Redda MG, Ragona R, et al:
Results of hypofractionated stereotactic re-irradiation on 13
locally recurrent nasopharyngeal carcinomas. Radiother Oncol.
53:23–28. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pan Y, Wang M, Bu X, et al: Curcumin
analogue T83 exhibits potent antitumor activity and induces
radiosensitivity through inactivation of Jab1 in nasopharyngeal
carcinoma. BMC Cancer. 13:3232013. View Article : Google Scholar
|
|
3
|
Wu JS, Brasher PM, El-Gayed A, et al:
Phase II study of hypofractionated image-guided radiotherapy for
localized prostate cancer: outcomes of 55 Gy in 16 fractions at 3.4
Gy per fraction. Radiother Oncol. 103:210–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schneider U, Besserer J and Mack A:
Hypofractionated radiotherapy has the potential for second cancer
reduction. Theor Biol Med Model. 7:42010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bakst RL, Lee N, Pfister DG, et al:
Hypofractionated dose-painting intensity modulated radiation
therapy with chemotherapy for nasopharyngeal carcinoma: a
prospective trial. Int J Radiat Oncol Biol Phys. 80:148–153. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Friedman JM, Jones PA and Liang G: The
tumor suppressor microRNA-101 becomes an epigenetic player by
targeting the polycomb group protein EZH2 in cancer. Cell Cycle.
8:2313–2314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang P, Rao EY, Meng N, Zhao Y and Wang
JJ: MicroRNA-17–92 significantly enhances radioresistance in human
mantle cell lymphoma cells. Radiat Oncol. 5:1002010.
|
|
8
|
Welch C, Chen Y and Stallings RL:
MicroRNA-34a functions as a potential tumor suppressor by inducing
apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu X, Luo HN, Tian WD, et al: Diagnostic
and prognostic value of plasma microRNA deregulation in
nasopharyngeal carcinoma. Cancer Biol Ther. 14:1133–1142. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen HC, Chen GH, Chen YH, et al: MicroRNA
deregulation and pathway alterations in nasopharyngeal carcinoma.
Br J Cancer. 100:1002–1011. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ghawanmeh T, Thunberg U, Castro J, Murray
F and Laytragoon-Lewin N: miR-34a expression, cell cycle arrest and
cell death of malignant mesothelioma cells upon treatment with
radiation, docetaxel or combination treatment. Oncology.
81:330–335. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu C, Zhou C, Gao F, et al: MiR-34a in
age and tissue related radio-sensitivity and serum miR-34a as a
novel indicator of radiation injury. Int J Biol Sci. 7:221–233.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang J, Kim E, Kim W, et al: Rhamnetin and
cirsiliol induce radiosensitization and inhibition of
epithelial-mesenchymal transition (EMT) by miR-34a-mediated
suppression of Notch-1 expression in non-small cell lung cancer
cell lines. J Biol Chem. 288:27343–27357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
John-Aryankalayil M, Palayoor ST, Makinde
AY, et al: Fractionated radiation alters oncomir and tumor
suppressor miRNAs in human prostate cancer cells. Radiat Res.
178:105–117. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boysen J, Sinha S, Price-Troska T, et al:
The tumor suppressor axis p53/miR-34a regulates Axl expression in
B-cell chronic lymphocytic leukemia: implications for therapy in
p53-defective CLL patients. Leukemia. 28:451–455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Su W, Hopkins S, Nesser NK, et al: The p53
transcription factor modulates microglia behavior through
microRNA-dependent regulation of c-Maf. J Immunol. 92:358–366.
2013.PubMed/NCBI
|
|
17
|
Stankevicins L, Almeida da Silva AP,
Ventura Dos Passos F, et al: MiR-34a is up-regulated in response to
low dose, low energy X-ray induced DNA damage in breast cells.
Radiat Oncol. 8:2312013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qu Y, Zhao S, Hong J and Tang S:
Radiosensitive gene therapy through imRNA expression for silencing
manganese superoxide dismutase. J Cancer Res Clin Oncol.
136:953–959. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feng XP, Yi H, Li MY, et al:
Identification of biomarkers for predicting nasopharyngeal
carcinoma response to radiotherapy by proteomics. Cancer Res.
70:3450–3462. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bourgier C, Lemanski C, Riou O, Charissoux
M, Fenoglietto P and Azria D: Hypofractionated radiotherapy, a
standard in breast cancer? Cancer Radiother. 17:705–707. 2013.(In
French).
|
|
21
|
Tortorelli G, Di Murro L, Barbarino R, et
al: Standard or hypofractionated radiotherapy in the postoperative
treatment of breast cancer: a retrospective analysis of acute skin
toxicity and dose inhomogeneities. BMC Cancer. 13:2302013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ishiyama H, Satoh T, Kitano M, et al:
High-dose-rate brachytherapy and hypofractionated external beam
radiotherapy combined with long-term hormonal therapy for high-risk
and very high-risk prostate cancer: outcomes after 5-year
follow-up. J Radiat Res. 55:509–517. 2013.PubMed/NCBI
|
|
23
|
Huang BS, Tsang NM, Lin SM, et al:
High-dose hypofractionated X-ray radiotherapy for hepatocellular
carcinoma: Tumor responses and toxicities. Oncol Lett. 6:1514–1520.
2013.PubMed/NCBI
|
|
24
|
Bush DA, Cheek G, Zaheer S, et al:
High-dose hypofractionated proton beam radiation therapy is safe
and effective for central and peripheral early-stage non-small cell
lung cancer: results of a 12-year experience at Loma Linda
University Medical Center. Int J Radiat Oncol Biol Phys.
86:964–968. 2013.PubMed/NCBI
|
|
25
|
Mouw KW and Harris JR: Hypofractionation
in the era of modulated radiotherapy (RT). Breast. 22(Suppl 2):
S129–S136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fowler JF: The radiobiology of prostate
cancer including new aspects of fractionated radiotherapy. Acta
Oncol. 44:265–276. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Debenham BJ, Hu KS and Harrison LB:
Present status and future directions of intraoperative
radiotherapy. Lancet Oncol. 14:e457–e464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mendrysa SM, Ghassemifar S and Malek R:
p53 in the CNS: perspectives on development, stem cells, and
cancer. Genes Cancer. 2:431–442. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Muaddi H, Chowdhury S, Vellanki R, Zamiara
P and Koritzinsky M: Contributions of AMPK and p53 dependent
signaling to radiation response in the presence of metformin.
Radiother Oncol. 108:446–450. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huerta S, Gao X, Dineen S, Kapur P, Saha D
and Meyer J: Role of p53, Bax, p21, and DNA-PKcs in radiation
sensitivity of HCT-116 cells and xenografts. Surgery. 154:143–151.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gilbert DC, Williams A, Allan K, et al:
p16INK4A, p53, EGFR expression and KRAS mutation status
in squamous cell cancers of the anus: correlation with outcomes
following chemo-radiotherapy. Radiother Oncol. 109:146–151.
2013.
|
|
32
|
Guo Y, Parry JJ, Laforest R, Rogers BE and
Anderson CJ: The role of p53 in combination radioimmunotherapy with
64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal
cancer. J Nucl Med. 54:1621–1629. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie X, Jin H, Hu J, et al: Association
between single nucleotide polymorphisms in the p53 pathway and
response to radiotherapy in patients with nasopharyngeal carcinoma.
Oncol Rep. 31:223–231. 2014.PubMed/NCBI
|
|
34
|
Yang CF, Peng LX, Huang TJ, et al: Cancer
stem-like cell characteristics induced by EB virus-encoded LMP1
contribute to radioresistance in nasopharyngeal carcinoma by
suppressing the p53-mediated apoptosis pathway. Cancer Lett.
344:260–271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Siemens H, Jackstadt R, Kaller M and
Hermeking H: Repression of c-Kit by p53 is mediated by miR-34 and
is associated with reduced chemoresistance, migration and stemness.
Oncotarget. 4:1399–1415. 2013.PubMed/NCBI
|
|
36
|
Yoshizaki T, Ito M, Murono S, Wakisaka N,
Kondo S and Endo K: Current understanding and management of
nasopharyngeal carcinoma. Auris Nasus Larynx. 39:137–144. 2012.
View Article : Google Scholar
|
|
37
|
Hermeking H: The miR-34 family in cancer
and apoptosis. Cell Death Differ. 17:193–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jain M, Arvanitis C, Chu K, et al:
Sustained loss of a neoplastic phenotype by brief inactivation of
MYC. Science. 297:102–104. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Doherty JR, Yang C, Scott KE, et al:
Blocking lactate export by inhibiting the Myc target MCT1 disables
glycolysis and glutathione synthesis. Cancer Res. 74:908–920. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yamamura S, Saini S, Majid S, et al:
MicroRNA-34a suppresses malignant transformation by targeting c-Myc
transcriptional complexes in human renal cell carcinoma.
Carcinogenesis. 33:294–300. 2012. View Article : Google Scholar : PubMed/NCBI
|
